The Association Between the Hemoglobin Glycation Index and Cardiometabolic Diseases: A Mini-Review.

The hemoglobin glycation index (HGI) has emerged as a pivotal biomarker for evaluating long-term glycemic control, offering a more comprehensive assessment compared with conventional glycated hemoglobin (HbA1c) measurements. Elevated HGI levels are significantly correlated with the incidence of cardiometabolic diseases (CMDs). This review synthesizes current evidence on the clinical utility of the HGI across coronary artery disease (CAD), hypertension, heart failure (HF), diabetes mellitus (DM), serum uric acid (SUA) levels, and nonalcoholic fatty liver disease (NAFLD), thereby providing clinicians with an enhanced framework for precise disease stratification, therapeutic optimization, and prognostic prediction.